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HIV transmission via breastfeeding accounts for a considerable proportion of infant HIV acquisition.
However, the origin and evolution of the virus population in breast milk, the likely reservoir of transmitted
virus variants, are not well characterized. In this study, HIV envelope (env) genes were sequenced from virus
variants amplified by single-genome amplification from plasmas and milk of 12 chronically HIV-infected,
lactating Malawian women. Maximum likelihood trees and statistical tests of compartmentalization revealed
interspersion of plasma and milk HIV env sequences in the majority of subjects, indicating limited or no
compartmentalization of milk virus variants. However, phylogenetic tree analysis further revealed monotypic
virus variants that were significantly more frequent in milk (median proportion of identical viruses, 29.5%;
range, 0 to 61%) than in plasma (median proportion of identical viruses, 0%; range, 0 to 26%) (P  0.002),
suggesting local virus replication in the breast milk compartment. Moreover, clonally amplified virus env genes
in milk produced functional virus Envs that were all CCR5 tropic. Milk and plasma virus Envs had similar
predicted phenotypes and neutralization sensitivities to broadly neutralizing antibodies in both transmitting
and nontransmitting mothers. Finally, phylogenetic comparison of longitudinal milk and plasma virus env
sequences revealed synchronous virus evolution and new clonal amplification of evolved virus env genes in milk.
The limited compartmentalization and the clonal amplification of evolving, functional viruses in milk indicate
continual seeding of the mammary gland by blood virus variants, followed by transient local replication of these
variants in the breast milk compartment.
Breast milk transmission of human immunodeficiency virus
(HIV) remains a significant mode of infant HIV acquisition
globally. This mode of mother-to-child HIV transmission ac-
counts for nearly half of the new infant HIV infections occur-
ring in developing nations (36), where formula feeding is as-
sociated with increased morbidity and mortality from
respiratory and diarrheal illnesses (51). Maternal (8, 24, 34, 48)
and infant (8, 23, 27, 33) antiretroviral prophylaxis during
breastfeeding is a promising strategy for reduction of breast
milk transmission of HIV; however, implementation of this
strategy is not widespread in areas of high HIV prevalence
(33). Furthermore, the toxicities associated with provision of
antiretroviral prophylaxis to mothers and infants during breast-
feeding and the clinical impact of the development of antiret-
roviral-resistant viruses during breastfeeding prophylaxis are
not well described for large populations.
While HIV transmission via breastfeeding accounts for a
significant proportion of infant HIV acquisition, the mecha-
nisms of this transmission and the pool of transmitted viruses
in breast milk are not well characterized. The magnitude of the
milk virus load has been associated with the risk of infant HIV
acquisition via breastfeeding (18, 45, 47), and therefore viruses
present in milk are the likely pool of viruses transmitted via
breastfeeding. Notably, milk HIV RNA loads remain 1 to 2 log
lower than those in plasma (18, 40), suggesting a lack of free
virus mixing between these compartments. Defining the origin
and genetic composition of viruses present in breast milk has
important implications for strategies to prevent breast milk
virus transmission.
Studies of HIV populations present in mucosal compart-
ments suggest that virus variants in the genital tract may be
distinct from the systemic virus population (2, 5, 21, 22). Di-
vergent mucosal immune responses may shape compartment-
specific viruses, as described for anatomic compartments such
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as semen and cervicovaginal fluid (2, 6, 9, 11, 21, 22, 37). Early
investigations of whether breast milk virus variants were com-
partmentalized from those in plasma were contradictory (5,
16). However, recent studies of HIV-infected lactating women
(13, 15, 16) and simian immunodeficiency virus (SIV)-infected
lactating monkeys (38) have suggested that the virus present in
milk is not genetically distinct from that in plasma. In addition,
recent human and primate studies of the virus population in
milk reported that groups of identical or nearly identical vi-
ruses were frequently detected in milk, suggesting that a pro-
portion of viruses present in milk are produced by infected
cells which are resident in the mammary gland (13, 15, 38).
However, the origin, persistence, and functionality of these
monotypic viruses are unknown. Thus, the production site,
virus trafficking patterns, and selection pressures that longitu-
dinally shape the genetic composition of the transmitted pool
of HIV variants remain to be characterized further.
In this study, full-length HIV env was amplified and sequenced
from plasma and milk of HIV-infected, breast milk-transmitting
and nontransmitting women by single-genome amplification, a
method that reduces the possibility of resampling and PCR-asso-
ciated error and virus recombination. Phylogenetic analysis and
statistical assessment of compartmentalization were applied to
the milk and plasma env sequences. Furthermore, HIV env se-
quences were cloned and used to make Env pseudoviruses for
assessment of tropism and neutralization sensitivity. Phylogenetic
and functional analyses of the full-length HIV env gene in these
anatomically distinct compartments, both cross-sectionally and
longitudinally, allow for insights into compartment-specific virus
production and sequence evolution of the pool of virus variants
present in the breast milk compartment.
MATERIALS AND METHODS
Subjects and sample collection and processing. Pregnant women testing HIV
positive by a rapid antibody test were recruited into this study (CHAVI 009) from
two rural health clinics outside Blantyre, Malawi. The study was approved by the
College of Medicine Research and Ethics Committee in Malawi and by all
participating institutions’ institutional review boards. Women were enrolled at
delivery if HIV infection was confirmed by HIV RNA and breastfeeding was
initiated. All mothers and infants in this study received single-dose nevirapine at
delivery. Maternal blood and left and right breast milk samples were collected 4
to 5 weeks and 3 months after delivery. Plasmas were isolated by Ficoll gradient
centrifugation, and breast milk supernatants were isolated by centrifugation to
separate the lipid and cellular portions. Twelve subjects who remained untreated
(except for single-dose nevirapine at delivery) and had detectable milk virus
loads (Table 1) were included in this substudy of HIV env diversity in breast milk
and plasma. env amplicons were able to be generated from milk and plasma of
each subject. None of the women included in the study had symptoms consistent
with clinical mastitis; however, three women (subjects 0404, 1209, and 3404) had
laboratory evidence of subclinical mastitis in the left breast, indicated by a milk
supernatant sodium concentration of 12 mM and a sodium/potassium ratio of
1 (measured by a Gen2 ion-selective electrode on a Roche Cobas c501 plat-
form [Roche Diagnostics]) (13, 47, 52). Three of the maternal subjects transmit-
ted the virus to their infants via breastfeeding (subjects 0404, 1209, and 4403), as
defined by an infant HIV DNA PCR result of negative at birth and 4 to 5 weeks
but positive by 6 months of age. All infants were monitored every 3 months until
the cessation of breastfeeding or 18 months of age.
Plasma and breast milk HIV loads. Plasma and milk virus loads were mea-
sured using the Roche Cobas Ampliprep/Cobas TaqMan 48 for HIV-1 viral load
assay. Breast milk supernatant was diluted 1:5 in phosphate-buffered saline
(PBS) prior to analysis. The minimum levels of detection for this assay are 48
viral RNA copies/ml of plasma and 240 viral RNA copies/ml of breast milk. The
laboratory performing these assays was enrolled in the National Institute of
Allergy and Infectious Diseases Division of AIDS Virology Quality Assessment
Program and certified for HIV load determinations.
Single-genome amplification and sequencing of the HIV env gene. Plasma
aliquots containing approximately 10,000 RNA copies were extracted using a
QIAamp Viral RNA Mini kit (Qiagen). Plasma samples with low viral loads and all
breast milk supernatant 1-ml aliquots were concentrated by centrifugation at 23,600
 g for 1 h at 4°C, and the virus pellet in approximately 100 l of leftover plasma or
milk supernatant was used for the same RNA extraction procedure. Depending on
the virus RNA load in milk (Table 1), between 200 and 10,000 RNA copies were
reverse transcribed. Single-strand cDNA synthesis was performed by using the Su-
perScript III protocol according to the manufacturer’s instructions (Invitrogen Life
Technologies). RNA, deoxynucleoside triphosphates (0.5 mM [each]), and 0.25 M
primer OFM19 (5-GCACTCAAGGCAAGCTTTATTGAGGCTTA-3) (corre-
sponding to nucleotides [nt] 9604 to 9632 of the HXB2 sequence) were incubated for
5 min at 65°C to denature the secondary structure of the RNA. First-strand cDNA
synthesis was carried out in 20-l to 60-l reaction mixtures with 1 reverse trans-
criptase buffer containing 5 mM dithiothreitol, 2 U/l of an RNase inhibitor (RNas-
eOut), and 10 U/l SuperScript III. The reaction mixture was incubated at 50°C for
60 min, followed by an additional hour at 55°C. Next, reactions were heat inactivated
at 70°C for 15 min, followed by RNase H digestion at 37°C for 20 min (Invitrogen
Life Technologies). The resulting cDNA was used immediately for PCR or stored
frozen at 80°C.
Full-length env genes were PCR amplified by single-genome amplification
methods as previously described (20, 46). Briefly, cDNA was titrated by end-
point dilution (undiluted to 1:40 dilution for breast milk cDNA) in 96-well PCR
plates to a concentration that yielded no more than 30% PCR-positive wells and
conformed to a Poisson distribution of a single template per reaction mix. PCR
conditions for first-round PCR consisted of 1 High Fidelity Platinum PCR
buffer, 2 mM MgSO4, a 0.2 mM concentration of each deoxynucleoside triphos-
phate, 0.2 M (each) primers Vif1 (5-GGGTTTATTACAGGGACAGCAGA
G-3; nt 4900 to 4923) and OFM19, and 0.025 U/l Platinum Taq High Fidelity
polymerase (Invitrogen) in a 20-l reaction mixture. The following PCR condi-
tions were used: 94°C for 2 min, followed by 35 cycles of 94°C for 15 s, 55°C for
30 s, and 68°C for 4 min, with a final extension of 68°C for 10 min. Second-round
PCR was carried out using 2 l of the first-round product and 0.2 M (each)
primers EnvA (5-GGCTTAGGCATCTCCTATGGCAGGAAGAA-3; nt 5954
to 5982) and EnvN (5-CTGCCAATCAGGGAAGTAGCCTTGTGT-3; nt
9145 to 9171) with the same PCR mixture as in the first round. The PCR
conditions included the following: 94°C for 2 min, followed by 45 cycles of 94°C
for 15 s, 55°C for 30 s, and 68°C for 4 min, with a final extension at 68°C for 10
min. The amplicons were sized in a precast 1% agarose E-gel 96 (Invitrogen Life
Technologies). Amplicons derived from cDNA dilutions yielding less than 30%
PCR positivity were sequenced using BigDye Terminator v.3.1 chemistry and the
protocols recommended by the manufacturer (Applied Biosystems). The se-
quences were determined by using an ABI 3730xl DNA analyzer (Applied Bio-
systems) and were edited by using the Sequencher program, version 4.9 (Gene
Codes). Both strands of DNA were sequenced. All chromatograms were care-
fully inspected for sites of ambiguous sequence (double peaks). A total of 702 env
sequences were inferred to be derived from a single cDNA template; sequences





Milk virus load in left/
right breast at 4 to 5 wk
postpartum (milk virus
load in left breast at 12
wk postpartum) (copies/ml)
0301 406 159,000 1,315/265
0404a 80 22,600 29,650/29,200
0601 295 346,000 478/1,290
0702 523 35,200 31,900/2,530
1209a 153 3,070 635/615 (460)
3009 273 202,000 770/489
3305 166 359,000 3,335/16,150
3404 548 72,400 102,500/860
3902 213 19,900 27,950/28,500 (1,095)
4403a 208 100,892 101,500/30,450 (240)
4707 247 83,400 10,500/22,500
5807 188 138,000 2,760/1,970
a Breast milk-transmitting subject.
b Subjects with laboratory evidence of subclinical mastitis are indicated with
shading.
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that displayed multiple double peaks in sequence chromatograms were excluded
from further analyses.
Phylogenetic sequence analysis. Sequences showing significant evidence of
APOBEC-driven G-to-A hypermutation, according to the Los Alamos National
Laboratory (LANL) HIV Sequence Database tool Hypermut 2.0 (44; http://www
.hiv.lanl.gov/content/sequence/HYPERMUT/hypermut.html), were excluded
from subsequent analyses. Sequence alignments were produced using ClustalW
(29) and were subsequently adjusted to optimize codon alignment. Regions that
could not be aligned unambiguously were omitted in further phylogenetic anal-
yses but were included in all other genetic and phenotypic analyses of the virus
populations. A neighbor-joining phylogenetic tree including sequences from all
12 subjects indicated that the sequences corresponding to each subject clustered
with high bootstrap support (100% [not shown]) (29). Additionally, the se-
quences from each subject were included in an analysis with 500 subtype C env
sequences to determine that in each case the subject sequences were monophy-
letic, to the exclusion of the other sequences (not shown). For each subject, a
maximum likelihood phylogenetic tree was inferred using PhyML, version 3.0
(14), and the results of approximate likelihood ratio tests (0.95) were used to
infer phylogenetic support (4). Recombination breakpoints in the sequence
alignment for each subject were detected using GARD (25).
Calculation of the proportion of clonally amplified virus variants, genetic
diversity, N-linked glycosylation site number, and variable region length.
Clonally amplified virus env sequences were defined as viruses that were
exactly identical to each other (0 nucleotide differences). Sequence diversity
was calculated using PAUP* (50). Sequence variability plots were generated
using the LANL Highlighter web tool (http://www.hiv.lanl.gov/content
/sequence/HIGHLIGHT/highlighter.html), using a plasma-derived sequence
nearest to the center node of the phylogenetic tree as the master sequence to
enhance detection of unique virus sequences or deletions in breast milk virus
variants. Potential N-linked glycosylation sites were enumerated in amino
acid sequences inferred from the nucleotide sequences (54). Amino acid
assignments to gp120 variable (V) regions were based on the LANL HXB2
spreadsheet (30; http://www.hiv.lanl.gov/content/sequence/HIV/MAP/hxb2
.xls) for determination of V region length.
HIV env cloning and pseudovirus production. HIV env genes amplified from
milk and plasma were reamplified from the first-round PCR product by use of
blunt-end primers and a low PCR cycle number to reduce PCR-induced se-
quence errors. Amplicon size was confirmed on an agarose gel, and the amplicon
was gel purified according to the manufacturer’s instructions (Qiagen). Purified
amplicons were ligated into pcDNA3.1 directional TOPO vectors (Invitrogen)
and used to transform TOP10 Escherichia coli cells per the manufacturer’s
instructions. Cultures were grown at 30°C, and selected colonies were screened
by miniprep and restriction digestion with XhoI and BamHI (New England
Biolabs). Plasmids with fragments of the correct size after restriction digestion
were sequenced to confirm sequence identity to the original env amplicon.
Confirmed env clones were grown in large cultures at 30°C. Plasmids were
prepared by megapreps (Qiagen) and resequenced to again confirm sequence
identity to the original env amplicon. Env pseudoviruses were prepared by trans-
fection into 293T cells of 4 g of env plasmid DNA and 8 g of env-deficient HIV
plasmid DNA, using the FuGENE 6 transfection reagent (Roche Diagnostic).
Two days after transfection, the culture supernatant containing pseudoviruses
was harvested, filtered, aliquoted, and stored at 80°C. An aliquot of stored
pseudovirus was used to measure infectivity in TZM-bl cells. Serial fivefold
dilutions of pseudovirus were distributed in quadruplicate in 96-well flat-bottom
plates (Costar) in a total volume of 100 l per well. Freshly trypsinized TZM-bl cells
were then added (10,000 cells/well in Dulbecco’s modified Eagle’s medium
[DMEM]–10% fetal bovine serum [FBS] containing HEPES and 25 g/ml of
DEAE-dextran). After 48 h of incubation, 100 l of cells/well was transferred to a
96-well black solid plate (Costar), and the luminescence was measured using a
Britelite Plus luminescence reporter gene assay system (Perkin-Elmer Life Sci-
ences). Wells producing relative luminescence units of 3 the background were
scored as positive, and the 50% tissue culture infective dose (TCID50) was calculated
by the method of Reed and Muench, as previously described (19, 31, 35). The
concentration of the pseudoviruses was measured using a commercial p24 enzyme-
linked immunosorbent assay (ELISA) (Perkin-Elmer Life Sciences) per its protocol.
The number of infectious units of each pseudovirus preparation is reported as the
TCID50/ng of p24 as a measure of infectivity per unit of virus (26).
Coreceptor usage and neutralization phenotype of HIV Env pseudoviruses.
Coreceptor usage was determined in TZM-bl cells by using TAK-779 (NIH
HIV reagent repository), a CCR5 receptor inhibitor, and AMD 3100 (NIH
HIV reagent repository), a CXCR4 antagonist. Freshly trypsinized TZM-bl
cells were distributed into 96-well plates (10,000 cells/well in DMEM–10%
FBS containing HEPES and 25 g/ml of DEAE-dextran) and incubated for
1 hour with either TAK-779 (10 M), AMD 3100 (1.3 M), a combination of
the two reagents, or no inhibitor (control wells). Pseudoviruses were diluted
to a predetermined concentration based on the TCID50 (a concentration
yielding the equivalent of 150,000 relative light units or at least 10 times the
background level). Diluted pseudoviruses were added to wells with the dif-
ferent treatments in triplicate, and the plates were incubated for 2 days. Cells
were lysed, and luciferase units were measured. Wells containing coreceptor
inhibitors were compared to control wells to determine if either agent led to
a reduction in infectivity. As controls, viruses known to use either CCR5 or
CXCR4 were included.
The neutralization phenotypes of the milk and plasma Env pseudoviruses were
determined in TZM-bl cells. The reagents used included soluble CD4 (sCD4;
Progenics, Tarrytown, NY); broadly neutralizing monoclonal antibodies 4E10,
2F5, 2G12 (all from Polymun Scientific, Inc., Vienna, Austria), and IgG1 B12
(Quality Biological, Gaithersburg, MD); HIV immunoglobulin (HIVIg) (ob-
tained from NVITAL, Gaithersburg, MD); and 5 polyclonal IgGs purified from
clade C HIV-infected sera. The HIV-infected sera were the top 5 neutralizers
among a large panel of HIV-infected sera from the South African National
Blood Services and were obtained from Lynn Morris (National Institute of
Communicable Diseases, Johannesburg, South Africa). Neutralization of the
Env-pseudotyped virus was measured as a reduction in luciferase gene expres-
sion, as previously described (35).
Statistical analysis. The proportions of genetically identical virus variants in
milk and plasma for each subject were compared by Fisher’s exact test with
Prism, version 5. Furthermore, the proportions of clonally amplified viruses in
milk and plasmas of all subjects were compared by the paired, nonparametric
Wilcoxon signed rank test. Evidence of compartmental structure was assessed
using programs implemented by HyPhy software (41), including the Slatkin-
Maddison (SM) test, which compares the minimum number of intercompart-
mental migration events to the frequency distribution of migration events in
1,000 randomized trees (42, 49), and the nearest neighbor statistic (Snn),
which compares how often the nearest sequence pairs were isolated from the
same or different compartments (17, 53) in 1,000 permutations. All other
comparisons of intra- and intersubject plasma and virus env sequence vari-
ables and milk factors, such as genetic diversity, N-linked glycosylation site
number, and cytokine concentration, were performed using the paired, non-
parametric Wilcoxon signed rank test with Prism, version 5. Correlations of
milk sodium concentration and cytokine concentration with breast milk virus
phenotypes were performed using Spearman’s rank test. Nonparametric sta-
tistics were employed due to the small number of subjects and virus variants
that could be amplified from the milk of some subjects. Statistical significance
was defined for P values of 0.05.
Nucleotide sequence accession numbers. All env sequences determined in this
study were deposited in GenBank under accession numbers HM070449 to
HM070824 and HQ595810 to HQ596189.
RESULTS
Limited phylogenetic compartmentalization of HIV variants
from the systemic virus population in the breast milk. Full-
length HIV env genes were amplified and sequenced from
plasma and breast milk supernatants collected 4 to 5 weeks
after delivery from 12 chronically HIV-infected, lactating
women (Table 1). All subjects received single-dose nevirapine
at delivery but otherwise remained off antiretroviral therapy.
Between 20 and 38 amplicons were generated from plasma,
and 9 to 79 amplicons were generated from breast milk sam-
ples (see Table 3), by single-genome amplification. Three sub-
jects with laboratory evidence of subclinical mastitis (sodium
concentration of 12 mM and a sodium/potassium ratio of
1) and three subjects who transmitted the virus to their
infants via breastfeeding (infant was HIV DNA negative at
birth and 4 to 5 weeks of age but was confirmed as being HIV
DNA positive at 6 weeks of age) were included in the study.
The median virus loads trended toward being significantly
higher in mastitic milk (median, 29,650 copies/ml; range, 635 to
102,500 copies/ml) than in nonmastitic milk (median, 3,335
copies/ml; range, 478 to 101,500 copies/ml) (P  0.06) but were
VOL. 85, 2011 ORIGIN AND EVOLUTION OF HIV-1 IN BREAST MILK 2753
not different in milk of transmitting (median, 29,650 copies/ml;
range, 635 to 101,500 copies/ml) and nontransmitting (median,
3,335, copies/ml; range, 478 to 102,500 copies/ml) subjects
(P  0.72). Interestingly, two of the three transmitting subjects
had laboratory evidence of subclinical mastitis, consistent with
the association of mastitis and the risk of breast milk transmis-
sion (47, 52).
Breast milk and plasma HIV env sequences were compared
by maximum likelihood phylogenetic analysis (Fig. 1). Impor-
tantly, breast milk HIV env gene sequences were interspersed
FIG. 1. HIV variants in milk do not appear to be compartmentalized from plasma virus variants in phylogenetic analyses yet display a higher
frequency of genetically identical virus variants than that of plasma virus variants. Trees from maximum likelihood analyses are shown for
full-length HIV env RNA nucleotide sequences amplified by single-genome amplification from milk (dark blue circles) and plasma (red circles)
from 12 chronically HIV-infected Malawian women (A to L). HIV env sequences amplified from milk from the left breast are identified with filled
circles, and those amplified from milk from the right breast are noted with stars. Open blue bars represent groups of identical viruses from the right
breast, and filled blue bars represent groups of identical viruses from the left breast. Numerals at nodes indicate approximate likelihood ratio test
values of 0.95. The scale bar represents 0.01 nuclear substitution per site. Groups of identical env sequences in plasma (red bars) or breast milk
(blue bars) are indicated and numbered.
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FIG. 1—Continued.
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among the plasma HIV env gene sequences on the phyloge-
netic trees comparing virus variants amplified from milk and
plasmas of all HIV-infected, lactating women (Fig. 1). A por-
tion of the milk virus variants clustered on an isolated branch
of the phylogenetic tree in three subjects (subjects 0404, 3009,
and 3404) (Fig. 1A, B, and C). Many of the milk virus variants
that clustered on a single branch in these subjects were iden-
tical or nearly identical sequences. The milk virus env se-
quences were not confined to a specific branch in the remain-
ing majority of the phylogenetic trees, indicating limited
compartmentalization of the breast milk virus population from
the circulating virus population in the majority of subjects.
Furthermore, the HIV env gene sequences of virus variants
amplified from milk collected from the right breast of three
subjects did not cluster separately from those amplified from
milk of the left breast from the same subjects (subjects 3902,
0301, and 4403) (Fig. 1F, K, and J). Moreover, the HIV env
sequences amplified from right breast milk clustered within
groups of identical viruses that included sequences amplified
from left breast milk for two subjects (subjects 3902 and 4403)
(Fig. 1F and J).
We then investigated the degree of compartmentalization of
the milk and blood sequences by both the SM test of the
minimum possible number of intercompartmental migration
events compared to the distribution of migration events in
1,000 randomized trees (39, 41, 49) and Hudson’s nearest-
neighbor statistic (Snn), which measures how often the nearest
neighbors of each sequence were isolated from the same or
different compartments (17, 53) (Table 2). Five of 12 subjects
had evidence of compartmentalization of milk and blood virus
sequences by either test (P  0.05). However, only the three
subjects with sequences from milk visibly isolated on a separate
branch of the maximum likelihood phylogenetic tree (subjects
0404, 3009, and 3404) (Fig. 1A, B, and C) exhibited significant
compartmentalization between blood and milk virus variants
by both tests. Interestingly, there was significant compartmen-
talization by phylogenetic and statistical analyses of viruses in
two of the three milk samples from subjects with laboratory
evidence of subclinical mastitis (subjects 0404 and 3404), a
finding that may be consistent with the high level of genetic
diversity in mastitic milk that has been described previously
(13). Furthermore, there was evidence of compartmentaliza-
tion by phylogenetic and statistical tests of compartmentaliza-
tion for one of the three breast milk-transmitting subjects (sub-
ject 0404).
Each of the subjects with evidence of significant compart-
mentalization by both tests had a large number of identical or
nearly identical sequences in milk (Table 3), which could con-
tribute to an overestimation of potential compartmentalization
(6, 7, 15). Therefore, the identical sequences within the same
compartment were removed from the data set subjected to the
SM and Snn analyses for all subjects. Significant compartmen-
talization between blood and milk virus variants remained ev-
ident for 6 of 12 subjects by the SM test, for 3 of 12 subjects by
the Snn test, and for 3 subjects (0404, 3009, and 3404) by both
tests (Table 2). However, the degree of significance was mar-
ginal for many of the subjects after removal of the repeated
identical sequences (P  0.02 to 0.04) (Table 2). Therefore, we
assessed the contribution of recombination to the tests of com-
partmentalization (1) for the three subjects with significant
compartmentalization in two statistical tests by repeating the
statistical tests on 4 or 5 segments of the genome that did not
contain a recombination breakpoint detected using GARD
(25). Both tests of compartmentalization for all nonrecom-
bined env segments remained significant for subject 0404,
whereas 2 of 5 env segments from subject 3009 and 1 of 4 env
segments from subject 3404 virus populations were no longer
significantly compartmentalized by the SM test (data not
shown). Therefore, there is evidence that the breast milk and
blood represent distinct anatomic compartments of HIV evo-
lution in only a minority of chronically HIV-infected, lactating
women.
Higher frequency of functional, clonally amplified virus
variants in breast milk virus populations than in plasma virus
populations. Notably, groups of identical or nearly identical
viruses appeared more commonly among breast milk virus
variants than among plasma virus variants in the majority of
subjects (Fig. 1; Table 3). In fact, groups of exactly identical
viruses (env sequences with 0 nucleotide differences) were sig-
nificantly more frequent among milk virus variants than among
plasma virus variants for 6 of 12 subjects by Fisher’s exact test
(Fig. 1; Table 3). Moreover, the median frequency of geneti-
cally identical virus variants in milk among the 12 subjects
(median, 28.5%; range, 0 to 61%) was significantly higher than
that in plasma (median, 0%; range, 0 to 26%) (P  0.002).
Interestingly, two subjects exhibited groups of identical env
sequences that included both plasma and breast milk virus
variants (subjects 4403 and 5807) (Fig. 1J and H). Further-
more, both right and left breast milk virus variants populated
the major cluster of genetically identical and nearly identical
virus variants in subject 4403 (Fig. 1J). The frequent occur-
rence of clonally amplified viruses in milk that are not phylo-
genetically distinct from those in plasma or the contralateral
breast suggests that cell-free or cell-associated virus in blood
traffics to the mammary gland and transiently replicates locally,
contributing to a proportion of the virus pool in the breast milk
compartment.
To explore the factors in the breast milk compartment that
TABLE 2. Results of SM and Snn tests of compartmentalization of











0301 0.19 0.05 0.19 0.05
0404a <0.0001 0.007 <0.0001 0.003
0601 0.001 0.16 0.02 0.48
0702 0.23 0.14 0.23 0.14
1209a 0.007 0.19 0.02 0.32
3009 <0.0001 <0.0001 0.04 0.02
3305 0.05 0.07 0.09 0.19
3404 0.002 <0.0001 0.03 0.001
3902 0.24 0.62 0.37 0.32
4403a 0.08 0.07 0.04 0.15
4707 0.10 0.85 0.19 0.27
5807 0.21 0.53 0.43 0.72
a Breast milk-transmitting subject.
b Subjects with laboratory evidence of subclinical mastitis are indicated with
shading. Significant P values (0.05) are shown in bold.
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may be associated with clonal amplification of milk virus, we
investigated the association of breast inflammation with the
frequency of genetically identical virus variants. Three of three
subjects with laboratory evidence of subclinical mastitis had
significantly higher proportions of genetically identical viruses
in milk than in blood, but the sodium concentration in milk did
not correlate with the proportion of monotypic viruses in milk
(r2  0.4; P  0.19). In addition, the two transmitting subjects
with mastitic milk in this cohort had significantly more mono-
typic viruses in milk than in plasma.
Consistent with the high frequency of identical viruses in
milk, the median percent genetic diversity in the HIV env
genes of the breast milk virus population was significantly
lower than that for the plasma virus population for five subjects
(0702, 1209, 3009, 3902, and 4403) (Table 3). This low genetic
diversity among breast milk virus variants compared to plasma
virus variants of these subjects likely reflects the large number
of genetically identical or nearly identical viruses in the milk of
these subjects (Fig. 1). The median percent genetic diversity in
the milk for the remaining subjects was either equal to (sub-
jects 0301, 0404, 4707, and 5807) or greater than (subjects
0601, 3305, and 3404) (Table 3) that in the plasma virus pop-
ulation, despite statistically greater proportions of genetically
identical virus env genes in milk of subjects 0601, 3404, and
0404 than those for plasma. Overall, there was no difference in
the median percent genetic diversity in the env gene for milk
(1.78%) and plasma (2.1%) viruses among all 12 subjects (P 
0.83) (Table 3). In addition, we did not find any association
between milk sodium concentration and the genetic distance of
the breast milk virus variants (r2  0.08; P  0.82). Notably, the
genetic diversity of milk virus variants was not consistently
lower than that of plasma virus variants, as might be expected
with divergent evolution of a small pool of anatomically com-
partmentalized virus variants.
We then assessed the functionality and coreceptor usage of
the clonally amplified virus env sequences identified in milk of
four HIV-infected, lactating women to assess if the monotypic
virus variants were functional and shared a consistent pheno-
type with that of transmitted/founder virus variants (20). env
sequences within groups of identical milk virus variants were
cloned and used to make pseudoviruses by transfection of 293T
cells. All of the clonally amplified milk env sequences tested
produced functional pseudoviruses that were able to infect
CD4 CCR5 TZM-bl cells with variable infectivity, measured
as the TCID50/ng p24 (Table 4). Furthermore, all of the
clonally amplified milk env pseudoviruses used CCR5, not
CXCR4, as the virus coreceptor (Table 4). Therefore, the
clonally amplified milk virus variants identified by env ampli-



















0301 Plasma 32 0 (0) NC 1.42 (0.04–6.03) 0.08
Milk 9 (1) 0 (0) 1.78 (0.08–3.39)
0404a Plasma 20 0 (0) 0.012 2.21 (0.12–5.90) 0.33
Milk 25 7 (28) 2.47 (0–5.77)
0601 Plasma 21 0 (0) 0.02 1.78 (0.08–13.7) <0.0001
Milk 23 6 (26) 2.47 (0–5.78)
0702 Plasma 21 0 (0) NC 1.54 (0.04–2.96) <0.0001
Milk 16 0 (0) 1.21 (0.04–2.22)
1209a Plasma 33 0 (0) 0.002 2.1 (0.08–3.84) 0.03
Milk 20 6 (30) 1.66 (0–3.23)
3009 Plasma 24 0 (0) <0.0001 2.1 (0.1–8.8) <0.0001
Milk 28 17 (61) 0.16 (0–8.65)
3305 Plasma 29 0 (0) 0.05 2.01 (0.86–6.2) <0.0001
Milk 30 5 (17) 2.5 (0–15.68)
3404 Plasma 20 0 (0) 0.004 1.16 (0.16–5.07) <0.0001
Milk 36 11 (31) 2.43 (0–4.04)
3902 Plasma 20 0 (0) 0.009 3.8 (0.04–9.46) <0.0001
Milk 21 (3) 7 (33) 1.34 (0–5.57)
4403a Plasma 38 9 (24) 0.81 1.42 (0–4.88) <0.0001
Milk 42 (37) 13 (31) 1.25 (0–5.53)
4707 Plasma 22 2 (9) 0.15 9.3 (0–11.35) 0.68
Milk 12 4 (33) 9.83 (0–11.24)
5807 Plasma 32 4 (12) 0.7 2.62 (0–6.53) 0.41
Milk 21 4 (19) 3.39 (0–6.63)
All subjects
(n  12)
Plasma 344 Median proportion,
0; range, 0–26
0.002 2.1 (0–13.7) 0.83
Milk 317 Median proportion,
29; range, 0–61
1.78 (0–15.7)
a Breast milk-transmitting subject.
b Subjects with laboratory evidence of subclinical mastitis are indicated with shading. Significant P values (0.05) are shown in bold.
c Calculated by including sequences from left breast milk only.
d NC, Fisher’s exact test is not calculable due to the presence of 0 monotypic viruses in both plasma and milk.
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fication and sequencing are likely functional and have a cellu-
lar tropism consistent with transmitted virus variants (20, 43).
Absence of an env genotype or phenotype unique to breast
milk virus variants. We next sought to determine if viruses
found in breast milk carry a unique HIV env genotype that
could differentiate breast milk viruses from circulating plasma
viruses. We first employed Highlighter plot sequence analy-
sis to compare breast milk HIV env gene sequences to
plasma HIV env gene sequences from each subject (data not
shown). The Highlighter plot analysis revealed no specific
virus env mutation or deletion that appeared consistently
among the milk virus variants and not in plasma virus vari-
ants. Therefore, we did not identify an HIV env gene se-
quence that defined a milk virus variant from a plasma virus
variant in these subjects.
We then used the virus env sequences to predict potential
Env phenotypic differences in breast milk and plasma viruses.
A larger number of N-linked glycosylation sites and deletions
in the env variable (V) loop region may confer virus neutral-
ization resistance, a phenotype that has been associated with
vertically transmitted viruses (10, 43). The median numbers of
N-linked glycosylation sites in the entire env gene product for
milk virus variants were significantly greater than those for
plasma virus variants for two subjects (3009 and 3902) and
were lower than those for plasma virus variants for two subjects
(0301 and 0601) (Table 5). While the median N-linked glyco-
sylation numbers were not vastly different in plasmas and milk
of those subjects with statistically significant differences in N-
linked glycosylation number, the ranges of the numbers of
predicted glycosylation sites in the large number of virus vari-
ants analyzed in those subjects were minimally overlapping,
leading to a statistical difference by the paired Wilcoxon rank
sum test. The remaining subjects had no significant difference
in the number of N-linked glycosylation sites of plasma and
virus variants. Furthermore, the median numbers of N-linked
glycosylation sites were similar in milk (30 sites) and plasma
(31 sites) virus env gene sequences among all 12 subjects (P 
0.14) (Table 5). Therefore, no consistent, distinct pattern in
the number of env glycosylation sites existed among milk virus
variants compared to plasma viruses of our subjects.
We next compared the V region lengths of milk and plasma
TABLE 4. Monotypic virus env genes in milk produce functional
virus envelopesa
Subject env amplicon Monotypicvirus groupb
Pseudovirus titer
(TCID50/ng of
p24) in TZM-bl cells
3305 bmC9 Gii 1,777.1
3305 bmF4 Gi 101.1
3902 bmG14 Fi 171.7
3902 bmH9 Fii 324.8
3902 bmD7 Fiii 14.1
4403 bmC5 Jiv 8.7
4403 bmB6 Ji 19.4
4707 bmF8 Ii 65.8
a All viruses demonstrated CCR5 coreceptor usage.
b Monotypic virus groups are indicated in Fig. 1.







P value Median V regionlength (range) P value
0301 Plasma 32 (31–33) 0.04 148 (143–152) 0.01
Milk 31 (29–32) 146.5 (139–148)
0404a Plasma 31 (28–33) 0.07 144.5 (141–149) 0.9
Milk 30 (28–33) 145 (141–146)
0601 Plasma 33 (30–36) 0.005 148 (138–157) 0.008
Milk 30 (30–36) 142 (142–156)
0702 Plasma 25 (24–27) 0.68 128 (127–131) 0.08
Milk 25 (25–27) 128 (127–132)
1209a Plasma 29 (24–35) 0.32 149 (138–161) 0.08
Milk 25 (24–32) 143 (138–160)
3009 Plasma 27 (26–34) 0.03 144 (142–160) 0.002
Milk 32 (26–34) 160 (142–160)
3305 Plasma 33 (29–34) 0.10 165 (146–173) 0.006
Milk 31 (29–33) 161 (134–167)
3404 Plasma 30.5 (29–33) 0.07 218 (218–235) 0.09
Milk 30 (27–31) 218 (214–236)
3902 Plasma 32.5 (27–33) 0.006 161 (137–167) 0.03
Milk 33 (31–34) 163 (151–167)
4403a Plasma 28 (27–33) 0.06 141 (139–149) 0.12
Milk 28 (25–32) 141 (122–153)
4707 Plasma 32 (25–38) 0.84 150 (130–161) 0.62
Milk 27 (25–35) 130 (130–158)
5807 Plasma 31 (27–34) 0.21 151 (128–156) 0.12
Milk 29 (27–34) 132 (128–155)
All subjects Plasma 31 (24–38) 0.14 148 (127–235) 0.19
Milk 30 (24–36) 143 (122–236)
a Breast milk-transmitting subject.
b Subjects with laboratory evidence of subclinical mastitis are indicated with shading. Significant P values (0.05) are shown in bold.
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virus variants. The V region lengths of breast milk virus vari-
ants were significantly shorter than those of plasma virus vari-
ants for three subjects (0301, 0601, and 3305) and were signif-
icantly longer than those for plasma virus variants for two
subjects (3009 and 3902) (Table 5). The median V region
lengths were not significantly different among plasma and milk
virus variants from the other subjects. Moreover, the overall
median V region lengths of milk (143 nucleotides) and plasma
(148 nucleotides) virus env sequences from all 12 subjects did
not differ significantly (P  0.19) (Table 5).
Finally, to determine if functionally distinct virus variants
are harbored in the breast milk compartment, suggesting dis-
tinct virus evolution in this compartment, we compared the
neutralization sensitivities of two to five plasma and milk Env
pseudoviruses from seven subjects. The milk and plasma Env
variants of each subject displayed comparable sensitivities to
plasma IgGs of chronically clade C HIV-infected patients with
broad neutralizing activity (SA C3, SA C6, SA C32, SA C26,
and SA C76) and to pooled HIVIg (Table 6). Typically, the
majority of the Env pseudoviruses from both compartments of
a single subject were uniformly resistant or susceptible to the
reagent. Occasionally, only one or two viruses from either the
milk or plasma compartment were resistant to the reagent.
Furthermore, the neutralization sensitivities of the breast milk
and plasma viruses from all subjects to HIVIg and plasma IgG
of the chronically HIV-infected subjects are consistent with a
tier 2 neutralization phenotype (31). Similarly, the milk and
plasma Env pseudoviruses within each subject displayed simi-
lar sensitivities to well-characterized broadly HIV-neutralizing
antibodies. The majority of the Env pseudoviruses from both
the milk and plasma of each subject were resistant to mono-
clonal antibodies 1B12 and 2G12. The sensitivities of the Env
TABLE 6. Milk- and plasma-derived envelope pseudoviruses display similar sensitivities to neutralization by sCD4, broadly neutralizing
monoclonal antibodies, and plasmas of chronically HIV-infected subjectsa
Pseudovirus Sampletype
Titer (50% infective dose)
SA C3 SA C9 SA C26 SA C32 SA C76 HIVIg 1B12 2G12 2F5 4E10 sCD4
3902.A7 Plasma 625 239.5 153.6 625 373.0 857.0 25 25 25 4.0 4.0
3902.B10 Plasma 625 111.8 625 131.4 221.0 2,500 24.9 25 24.6 7.6 5.2
3902.G3 Plasma 625 196.7 625 625 123.2 1,670.0 25 25 14.2 7.7 14.1
3902.G10 Plasma 625 625 625 625 625 2,399.0 25 25 20.1 6.1 24.8
3902.G12 Plasma 461.4 122.8 31.1 138.4 197.3 1,504.0 25 25 25 8.0 3.8
3902.BMD7 Milk 197.5 131.4 31.5 126.3 231.0 2,500 25 25 25 24.1 4.4
3902.BME6 Milk 625 198.5 39.7 427.6 295.3 1,848.0 25 25 25 18.0 6.2
3902.BMG14 Milk 625 80.8 86.6 164.0 202.7 1,971.0 13.6 25 19.4 11.5 1.9
3902.BMG24 Milk 625 62.7 23.0 176.4 149.9 1,598.0 25 25 15.0 7.1 4.3
3305.A7 Plasma 625 625 625 625 625 2,500 25 25 25 25 25
3305.A10 Plasma 625 625 276.6 625 625 2,500 25 25 25 6.7 25
3305.C4 Plasma 625 625 625 625 625 2,500 25 25 25 11.9 20.2
3305.E9 Plasma 625 625 255.3 625 406.7 2,500 25 25 25 14.0 23.2
3305.BMC1 Milk 625 625 414.0 625 446.6 2,500 25 25 25 5.8 25
3305.BMC9 Milk 625 625 271.6 625 476.3 2,500 25 25 25 17.1 25
3305.BMC11 Milk 625 625 40.3 625 625 2,500 25 25 25 13.2 15.8
3305.BMF4 Milk 625 625 625 625 625 2,500 25 25 25 8.4 25
3305.BMF6 Milk 625 625 381.9 625 575.2 2,500 25 25 25 14.0 25
4403.A18 Plasma 195.4 49.5 625 32.2 138.5 1,612.7 25 25 25 25 8.2
4403.D1 Plasma 184.4 41.5 625 38.9 145.5 679.9 25 25 25 25 5.0
4403.H2 Plasma 112.8 44.6 625 38.5 111.9 1,064.1 25 25 25 25 4.0
4403.H7 Plasma 346.7 71.4 625 49.0 181.7 1,380.3 25 25 25 25 5.1
4403.BMB6 Milk 272.4 58.9 625 45.8 158.3 523.6 25 25 25 25 3.1
4403.BMB10 Milk 204.4 44.7 625 33.7 125.0 1,320.3 25 25 25 25 4.3
4403.BMC5 Milk 302.6 58.8 625 48.7 154.8 1,090.1 25 25 25 25 4.8
0301.A8 Plasma 310.6 16.6 133.3 48.4 55.6 632.1 25 25 9.3 11.1 3.5
0301.D1 Plasma 197.4 30.7 119.8 53.2 62.2 984.7 25 25 5.6 7.7 7.8
0301.E8 Plasma 323.4 73.2 149.0 69.7 111.0 1,800.7 25 25 20.3 18.3 6.4
0301.BMA2 Milk 230.2 15.3 104.6 36.5 45.0 1,229.7 25 25 10.0 16.9 2.2
0301.BMA6 Milk 40.4 5.2 625 24.8 18.9 576.8 25 25 9.8 12.2 5.7
0301.BMA12 Milk 111.3 22.1 499.1 40.4 44.3 1,133.6 25 25 8.3 10.1 3.8
47707.E1 Plasma 625 293.9 625 79.0 277.1 2,500 25 25 25 25 25
47707.G3 Plasma 365.2 293.9 511.0 281.8 625 2,500 25 25 25 6.9 1.2
47707.H8 Plasma 625 625 625 625 625 2,500 25 25 25 25 10.3
47707.BMF8 Milk 625 625 625 549.2 625 2,500 25 25 25 25 6.6
47707.BMAH2 Milk 625 139.1 625 105.1 171.8 2,500 25 25 25 25 10.5
0702.A5 Plasma 625 368.4 249.2 234.2 107.8 1,635.2 25 25 25 3.9 25
0702.B12 Plasma 625 521.0 625 388.6 141.7 944.9 25 25 25 10.2 25
0702.F21 Plasma 248.6 564.6 177.6 463.2 122.9 1,408.5 25 25 25 5.2 25
0702.G6 Plasma 185.3 507.0 82.2 217.8 83.2 2,500 25 25 25 5.4 11.8
0702.BMB4 Milk 625 336.5 625 175.2 80.4 1,998.3 25 25 25 5.6 25
0702.BMB9 Milk 625 537.6 338.3 308.8 116.7 1,897.2 25 25 25 3.6 13.4
0702.BMH12 Milk 625 544.4 625 333.6 97.3 1,368.6 25 25 25 4.8 11.1
a Shading represents detectable neutralization.
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pseudoviruses to 2F5 were either uniform in both the milk
and plasma compartments or unique to a portion of the vari-
ants from both compartments. The sensitivities of the Env
pseudoviruses to 4E10 were typically uniform in both the milk
and plasma compartments or unique to just a single variant
from the plasma compartment. Finally, all or a portion of the
Env pseudoviruses from each compartment within each subject
were susceptible to neutralization by sCD4.
Based on these data, breast milk viruses do not appear to
have a distinct env gene sequence, predicted env gene product
phenotype, or functional neutralization phenotype compared
to plasma viruses. This uniform appearance of the milk and
plasma virus env genotype and phenotype further supports the
lack of compartmentalization of virus in milk and the continual
seeding of the breast milk compartment by circulating virus
variants. Moreover, the similar predicted Env phenotypes and
neutralization sensitivities of milk and plasma virus Envs indi-
cate that milk and plasma viruses evolve under similar immune
pressures. Interestingly, the breast milk virus env genotype,
N-linked glycosylation number, and V region length were not
distinct from those in plasma in the three transmitting subjects
included in this study.
Continual seeding of the breast milk compartment from the
blood virus population. Finally, we sought to determine
whether the breast milk virus population undergoes distinct
virus evolution from that in plasma over time. We amplified
and sequenced the virus env genes from blood and breast milk
virus variants of two subjects at 4 to 5 weeks and 3 months
postpartum and phylogenetically compared the compartment-
specific longitudinal env sequences (Fig. 2). The breast milk
and plasma sequences evolved synchronously between 4 to 5
weeks and 3 months postpartum in both subjects and contin-
ued to intermingle on the phylogenetic tree at 3 months post-
partum. Therefore, breast milk virus variants do not appear to
evolve distinctly over time. Importantly, we did not see persis-
tence of the same groups of genetically identical viruses
present at 4 to 5 weeks postpartum. Furthermore, groups of
identical viruses appeared in milk at 3 months postpartum that
were not present at 4 to 5 weeks postpartum in subject 1209,
indicating local virus replication in the breast milk compart-
ment of newly evolved virus variants recently seeded from the
circulation. The appearance of new groups of identical viruses
longitudinally in milk that are closely related to concurrent
blood virus variants is evidence of ongoing seeding of the
breast milk compartment by the systemic virus population,
followed by repeated, transient bursts of virus replication in
milk.
DISCUSSION
The statistically significantly larger proportion of genetically
identical viruses in breast milk than in plasma for 6 of 12
subjects in this cohort, identified by a sequencing method that
limits the possibility of virus resampling (20, 46), is striking.
Moreover, the milk virus env sequences from these groups of
identical viruses produced functional pseudovirions, indicating
that the groups of identical virus env sequences represent rep-
lication of functional virus variants. This clonal amplification of
virus variants has been described for milk of chronically SIV-
infected, lactating monkeys (38) and HIV-infected, lactating
women (13, 15). However, the presence of genetically identical
viruses in HIV-infected, lactating women has not been con-
firmed previously by strict single-virus RNA genome amplifi-
cation or assessed for functionality and persistence. While we
used only genetically identical env genes for statistical analysis
of monotypic viruses in milk and plasma in this study, the
nearly identical viruses that cluster together on the phyloge-
netic trees certainly also represent clonally amplified variants,
given the large amount of sequence diversity within a single
chronically HIV-infected individual. Therefore, our report of
the frequency of only the genetically identical viruses in milk
likely underestimates the true frequency of clonally amplified
viruses in milk. The high frequency of genetically identical and
nearly identical clonally amplified virus variants in milk indi-
cates that infected cells that have trafficked to or are resident
in the mammary gland may produce at least a portion of the
viruses present in the milk.
Despite evidence that breast milk virus may be produced by
infected cells resident in the breast milk compartment, we
found limited evidence of phylogenetic compartmentalization
and distinct evolution of viruses in breast milk from that of
circulating viruses by maximum likelihood tree analysis and
phylogenetic and genetic distance-based tests of compartmen-
talization for the majority of subjects. Furthermore, longitudi-
nal env sequencing of milk and plasma virus variants revealed
analogous virus evolution over time, indicating ongoing seed-
ing of the breast milk virus population by blood variants. This
lack of compartmentalization of virus in milk in the majority of
subjects is in contrast to studies of virus populations in the
male and female genital tracts, where compartmentalization of
virus in genital secretions is frequently observed in the majority
of subjects studied (1, 2, 6, 9, 11, 21, 22, 37). These contrasting
results may indicate a difference in virus trafficking from the
systemic circulation to the genital tract and the breast milk
compartment (38). Moreover, comparison of the levels of ge-
netic diversity of the HIV env sequences of breast milk and
plasma virus populations did not reveal consistently low ge-
netic diversity among breast milk virus variants, which might be
expected of a compartmentalized, small pool of virus that
evolves distinctly from circulating virus. However, the women
included in this study were selected for detectable virus loads
in milk, and therefore, it is possible that the degree of com-
partmentalization of milk virus is substantial in women with
FIG. 2. Milk and plasma HIV variants evolve similarly over time, with clonal amplification of new virus variants in milk. Trees from maximum
likelihood analyses are shown for full-length HIV env RNA nucleotide sequences amplified by single-genome amplification from milk (dark blue
circles) and plasmas (red circles) obtained at 4 to 5 weeks and from milk (light blue squares) and plasmas (pink squares) obtained 3 months after
delivery from two chronically HIV-infected, lactating women. Numerals at nodes indicate approximate likelihood ratio test values of 0.95. The
scale bar represents 0.01 nuclear substitution per site. Groups of identical sequences in plasma at 4 to 5 weeks (red bars) and 3 months (pink bars)
or in breast milk at 4 to 5 weeks (dark blue bars) and 3 months (light blue bars) are indicated.
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low milk virus loads. Although early studies employing phylo-
genetic analysis of the variable region of HIV env after bulk
cloning of breast milk and plasma viruses were contradictory as
to whether these virus populations were compartmentalized (5,
16), the application of single-genome amplification of full-
length HIV env and the consistency with data from nonhuman
primate models (38) and other human cohorts (13, 15) in-
crease the strength of our finding that breast milk viruses are
not compartmentalized phylogenetically from plasma viruses
in the majority of subjects.
Interestingly, two subjects displayed groups of identical and
nearly identical viruses that included both blood and milk virus
sequences (subjects 4403 and 5807). Furthermore, both right
and left breast milk virus variants populated the major cluster
of genetically identical and nearly identical virus variants for
subject 4403. Moreover, the genetic diversity of virus env se-
quences in milk samples that displayed a large proportion of
clonally amplified virus variants was not always more restricted
than that in plasma (subjects 0601, 3305, and 3404). These
findings, paired with the appearance of new clusters of clonally
amplified virus variants that are closely related to concurrent
blood virus variants in longitudinal milk virus sequencing, in-
dicate ongoing bursts of local virus replication after seeding of
the milk compartment by circulating virus variants. In fact, a
recent comparison of breast milk HIV env genetic diversity in
antiretroviral-treated women revealed virus evolution under
selective drug pressure in milk that was distinct from that in
plasma, implicating local replication of breast milk virus (3).
This insight into the location of milk virus replication is im-
portant to the design of immunologic interventions to reduce
virus content in the milk, as decreasing milk virus loads would
likely lead to a reduction in the risk of transmission of HIV via
breastfeeding.
Finally, full-length HIV env sequencing of the milk virus
population allowed us to assess whether a distinct virus env
sequence, predicted virus Env phenotype, or neutralization
sensitivity was unique to breast milk virus env genes. Analysis
of milk virus env mutations and deletions compared to those in
plasma HIV env sequences did not reveal a signature sequence
or deletion unique to breast milk viruses. Furthermore, milk
virus env sequences were not consistently predicted to be gly-
cosylated more or less than those of plasma viruses, did not
consistently have a longer or shorter V region length than that
of plasma viruses, and were not distinctly resistant to neutral-
ization by plasmas of chronically HIV-infected subjects or
broadly HIV-neutralizing antibodies. Therefore, while neutral-
ization-resistant viruses have been associated with breast milk
transmission of HIV (43), a neutralization-resistant env phe-
notype consisting of a small number of N-linked glycosylation
sites and deletions in the variable loops (28, 32) was not more
common in breast milk viruses than in plasma viruses. This lack
of a predicted Env phenotype or neutralization phenotype
unique to breast milk virus variants suggests that plasma and
breast milk viruses are not compartmentalized from each other
and evolve under similar humoral immune pressures.
Importantly, we did not find evidence of distinct breast milk
virus evolution, a distinct degree of local virus replication, or a
predicted virus Env phenotype in milk of transmitting subjects
compared to nontransmitting subjects. This finding suggests
that the degree of local breast milk virus replication or the
virus Env phenotype may not contribute to the risk of virus
transmission via breastfeeding. Subclinical mastitis, which is
known to increase the risk of breast milk virus transmission
(12, 18, 47, 52), was associated with long genetic distances
between plasma and milk virus variants in a recent report (13).
In our study, subclinical mastitis was associated with a large
proportion of clonally amplified viruses in milk for three of
three subjects with mastitic milk (subjects 0404, 1209, and
3404), with evidence of compartmentalization between plasma
and milk virus variants for two of three subjects with mastitic
milk (subjects 0404 and 3404), and with higher genetic diversity
of milk viruses than plasma viruses for one of three subjects
with mastitic milk (subject 3404). These findings may suggest
increased kinetics of virus replication in the breast milk com-
partment during subclinical mastitis and breast inflammation.
Therefore, the possibility of increased local virus replication as
a result of inflammatory processes in the mammary gland lead-
ing to a high risk of virus transmission via breast milk should be
investigated further.
The absence of phylogenetic compartmentalization, distinct
virus evolution, or unique virus env genetic or phenotypic fea-
tures of milk viruses compared to those in plasma suggests that
viruses in breast milk are replenished from the pool of circu-
lating viruses. However, the high frequency of clonally ampli-
fied virus variants in milk suggests that a relatively small num-
ber of productively infected cells in mammary tissue transiently
contribute a disproportionately large number of virions to the
virus pool in milk. Therefore, there may be two mechanisms by
which virus populates the breast milk compartment. The first is
continual trafficking of cell-free or cell-associated virus from
blood into the breast milk compartment. The second is tran-
sient local production of virus recently trafficked from the
blood by HIV-infected cells in the mucosa of the mammary
gland or in the milk. Therefore, immunologic and antiretrovi-
ral drug interventions to decrease breast milk virus load as a
strategy to reduce transmission of HIV via breastfeeding may
need to target both blood-derived virus trafficking into the
mammary gland and local replication of HIV within the breast
milk compartment.
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